In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia

H SISWANTORO, Bruce Russell, A RATCLIFF, Prasetyorini, Ferryanto Chalfein, Jutta Marfurt, Enny Kenangalem, R Wuwung, Kim Piera, E Ebsworth, Nicholas Anstey, Emiliana Tjitra, Ric Price

    Research output: Contribution to journalArticle

    Abstract

    Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC50 for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times. Copyright � 2011 American Society for Microbiology. All Rights Reserved.
    Original languageEnglish
    Pages (from-to)197-202
    Number of pages6
    JournalAntimicrobial Agents and Chemotherapy
    Volume55
    Issue number1
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Plasmodium malariae
    Indonesia
    Chloroquine
    Trophozoites
    Parasites
    Malaria
    In Vitro Techniques
    Confidence Intervals
    Schizonts
    Parasitemia
    Antimalarials
    Microbiology
    Pharmaceutical Preparations

    Cite this

    SISWANTORO, H ; Russell, Bruce ; RATCLIFF, A ; Prasetyorini ; Chalfein, Ferryanto ; Marfurt, Jutta ; Kenangalem, Enny ; Wuwung, R ; Piera, Kim ; Ebsworth, E ; Anstey, Nicholas ; Tjitra, Emiliana ; Price, Ric. / In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 1. pp. 197-202.
    @article{26a447341d5a4c2da899c4185475c605,
    title = "In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia",
    abstract = "Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95{\%} confidence interval [CI], 57 to 114) for P. malariae and 150 (95{\%} CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93{\%} of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50{\%} effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC50 for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times. Copyright � 2011 American Society for Microbiology. All Rights Reserved.",
    keywords = "chloroquine, doxycycline, primaquine, quinine, adolescent, anemia, antimalarial drug susceptibility, article, child, drug efficacy, female, gametocyte, human, in vitro study, in vivo study, Indonesia, major clinical study, male, nonhuman, Plasmodium malariae, Plasmodium malariae infection, Plasmodium ovale, Plasmodium ovale malaria, preschool child, priority journal, schizont, school child, trophozoite, Adolescent, Adult, Antimalarials, Child, Child, Preschool, Chloroquine, Female, Humans, Malaria, Male, Middle Aged, Treatment Outcome, Young Adult",
    author = "H SISWANTORO and Bruce Russell and A RATCLIFF and Prasetyorini and Ferryanto Chalfein and Jutta Marfurt and Enny Kenangalem and R Wuwung and Kim Piera and E Ebsworth and Nicholas Anstey and Emiliana Tjitra and Ric Price",
    year = "2011",
    doi = "10.1128/AAC.01122-10",
    language = "English",
    volume = "55",
    pages = "197--202",
    journal = "Antimicrobial Agents and Chemotherapy",
    issn = "0066-4804",
    publisher = "American Society for Microbiology",
    number = "1",

    }

    SISWANTORO, H, Russell, B, RATCLIFF, A, Prasetyorini, Chalfein, F, Marfurt, J, Kenangalem, E, Wuwung, R, Piera, K, Ebsworth, E, Anstey, N, Tjitra, E & Price, R 2011, 'In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia', Antimicrobial Agents and Chemotherapy, vol. 55, no. 1, pp. 197-202. https://doi.org/10.1128/AAC.01122-10

    In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. / SISWANTORO, H; Russell, Bruce; RATCLIFF, A; Prasetyorini; Chalfein, Ferryanto; Marfurt, Jutta; Kenangalem, Enny; Wuwung, R; Piera, Kim; Ebsworth, E; Anstey, Nicholas; Tjitra, Emiliana; Price, Ric.

    In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 1, 2011, p. 197-202.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - In Vivo and In Vitro Efficacy of Chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia

    AU - SISWANTORO, H

    AU - Russell, Bruce

    AU - RATCLIFF, A

    AU - Prasetyorini, null

    AU - Chalfein, Ferryanto

    AU - Marfurt, Jutta

    AU - Kenangalem, Enny

    AU - Wuwung, R

    AU - Piera, Kim

    AU - Ebsworth, E

    AU - Anstey, Nicholas

    AU - Tjitra, Emiliana

    AU - Price, Ric

    PY - 2011

    Y1 - 2011

    N2 - Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC50 for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times. Copyright � 2011 American Society for Microbiology. All Rights Reserved.

    AB - Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC50 for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times. Copyright � 2011 American Society for Microbiology. All Rights Reserved.

    KW - chloroquine

    KW - doxycycline

    KW - primaquine

    KW - quinine

    KW - adolescent

    KW - anemia

    KW - antimalarial drug susceptibility

    KW - article

    KW - child

    KW - drug efficacy

    KW - female

    KW - gametocyte

    KW - human

    KW - in vitro study

    KW - in vivo study

    KW - Indonesia

    KW - major clinical study

    KW - male

    KW - nonhuman

    KW - Plasmodium malariae

    KW - Plasmodium malariae infection

    KW - Plasmodium ovale

    KW - Plasmodium ovale malaria

    KW - preschool child

    KW - priority journal

    KW - schizont

    KW - school child

    KW - trophozoite

    KW - Adolescent

    KW - Adult

    KW - Antimalarials

    KW - Child

    KW - Child, Preschool

    KW - Chloroquine

    KW - Female

    KW - Humans

    KW - Malaria

    KW - Male

    KW - Middle Aged

    KW - Treatment Outcome

    KW - Young Adult

    UR - http://www.scopus.com/inward/record.url?scp=78650647223&partnerID=8YFLogxK

    U2 - 10.1128/AAC.01122-10

    DO - 10.1128/AAC.01122-10

    M3 - Article

    VL - 55

    SP - 197

    EP - 202

    JO - Antimicrobial Agents and Chemotherapy

    JF - Antimicrobial Agents and Chemotherapy

    SN - 0066-4804

    IS - 1

    ER -